183 related articles for article (PubMed ID: 34076745)
1. Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy.
van de Donk PP; Wind TT; Hooiveld-Noeken JS; van der Veen EL; Glaudemans AWJM; Diepstra A; Jalving M; de Vries EGE; de Vries EFJ; Hospers GAP
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4369-4376. PubMed ID: 34076745
[TBL] [Abstract][Full Text] [Related]
2.
Nienhuis PH; Antunes IF; Glaudemans AWJM; Jalving M; Leung D; Noordzij W; Slart RHJA; de Vries EFJ; Hospers GAP
J Nucl Med; 2022 Jun; 63(6):899-905. PubMed ID: 34503964
[TBL] [Abstract][Full Text] [Related]
3. N-(4-18F-fluorobenzoyl)interleukin-2 for PET of human-activated T lymphocytes.
Di Gialleonardo V; Signore A; Glaudemans AW; Dierckx RA; De Vries EF
J Nucl Med; 2012 May; 53(5):679-86. PubMed ID: 22499614
[TBL] [Abstract][Full Text] [Related]
4. Development and Evaluation of Interleukin-2-Derived Radiotracers for PET Imaging of T Cells in Mice.
van der Veen EL; Suurs FV; Cleeren F; Bormans G; Elsinga PH; Hospers GAP; Lub-de Hooge MN; de Vries EGE; de Vries EFJ; Antunes IF
J Nucl Med; 2020 Sep; 61(9):1355-1360. PubMed ID: 32111688
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
[No Abstract] [Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic modelling of N-(4-[(18)F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation.
Di Gialleonardo V; Signore A; Willemsen AT; Sijbesma JW; Dierckx RA; de Vries EF
Eur J Nucl Med Mol Imaging; 2012 Oct; 39(10):1551-60. PubMed ID: 22777334
[TBL] [Abstract][Full Text] [Related]
8. Assessing immune organs on
Prigent K; Lasnon C; Ezine E; Janson M; Coudrais N; Joly E; Césaire L; Stefan A; Depontville M; Aide N
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2573-2585. PubMed ID: 33432374
[TBL] [Abstract][Full Text] [Related]
9. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
Seban RD; Moya-Plana A; Antonios L; Yeh R; Marabelle A; Deutsch E; Schwartz LH; Gómez RGH; Saenger Y; Robert C; Ammari S; Dercle L
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2301-2312. PubMed ID: 32206839
[TBL] [Abstract][Full Text] [Related]
10. Uptake of Radium-223 Dichloride and Early [
Letellier A; Johnson AC; Kit NH; Savigny JF; Batalla A; Parienti JJ; Aide N
Mol Imaging Biol; 2018 Jun; 20(3):482-491. PubMed ID: 29027074
[TBL] [Abstract][Full Text] [Related]
11. CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of
Farwell MD; Gamache RF; Babazada H; Hellmann MD; Harding JJ; Korn R; Mascioni A; Le W; Wilson I; Gordon MS; Wu AM; Ulaner GA; Wolchok JD; Postow MA; Pandit-Taskar N
J Nucl Med; 2022 May; 63(5):720-726. PubMed ID: 34413145
[TBL] [Abstract][Full Text] [Related]
12.
Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study.
Hartimath SV; Manuelli V; Zijlma R; Signore A; Nayak TK; Freimoser-Grundschober A; Klein C; Dierckx RAJO; de Vries EFJ
Oncotarget; 2018 Jan; 9(6):7162-7174. PubMed ID: 29467958
[TBL] [Abstract][Full Text] [Related]
14. Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma.
Ferdinandus J; Zaremba A; Zimmer L; Umutlu L; Seifert R; Barbato F; Ugurel S; Chorti E; Grünwald V; Herrmann K; Schadendorf D; Fendler WP; Livingstone E
Cancer Imaging; 2022 Feb; 22(1):11. PubMed ID: 35123578
[TBL] [Abstract][Full Text] [Related]
15. Is there a link between very early changes of primary and secondary lymphoid organs in
Seith F; Forschner A; Weide B; Gückel B; Schwartz M; Schwenck J; Othman AE; Fenchel M; Garbe C; Nikolaou K; Schwenzer N; la Fougère C; Pfannenberg C
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753543
[TBL] [Abstract][Full Text] [Related]
16. Clinical-grade N-(4-[
van der Veen EL; Antunes IF; Maarsingh P; Hessels-Scheper J; Zijlma R; Boersma HH; Jorritsma-Smit A; Hospers GAP; de Vries EGE; Lub-de Hooge MN; de Vries EFJ
EJNMMI Radiopharm Chem; 2019 Jul; 4(1):15. PubMed ID: 31659562
[TBL] [Abstract][Full Text] [Related]
17. FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With Pembrolizumab.
Yeh R; Trager MH; Rizk EM; Finkel GG; Barker LW; Carvajal RD; Geskin LJ; Schwartz GK; Schwartz L; Dercle L; Saenger YM
Clin Nucl Med; 2020 Apr; 45(4):267-275. PubMed ID: 32108700
[TBL] [Abstract][Full Text] [Related]
18. PET of malignant melanoma using 18F-labeled metallopeptides.
Ren G; Liu Z; Miao Z; Liu H; Subbarayan M; Chin FT; Zhang L; Gambhir SS; Cheng Z
J Nucl Med; 2009 Nov; 50(11):1865-72. PubMed ID: 19837749
[TBL] [Abstract][Full Text] [Related]
19. (18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients.
Iagaru A; Mosci C; Shen B; Chin FT; Mittra E; Telli ML; Gambhir SS
Radiology; 2014 Nov; 273(2):549-59. PubMed ID: 25033190
[TBL] [Abstract][Full Text] [Related]
20. The utility of
Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
